Merck Delivers Solid Q3 2026 Results and Advances Strategic Priorities Across the Business

On November 12, 2026 Merck, a leading science and technology company, reported solid growth in the third quarter of 2026. Performance was driven by Process Solutions, Rare Diseases and Semiconductor Solutions, in line with the company’s focus on high growth value drivers. Group net sales increased to € 5.6 billion year-on-year (Q3 2025: € 5.3 billion), up 5.1% organically. EBITDA pre amounted to € 1.7 billion (Q3 2025: € 1.7 billion). The organic growth of 0.4% reflects a high basis of comparison in the year-earlier quarter, which benefited from several one-time effects. Merck has raised its financial guidance for the full year 2026 and now expects net sales to be between € 21.5 billion and € 21.9 billion and EBITDA pre to be between € 6.2 billion and € 6.4 billion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our third-quarter performance underscores the strength of our integrated business model with our strong position in attractive growth markets, especially biomanufacturing, discovery and development across the life sciences value chain, semiconductor manufacturing that supports AI and advanced nodes, as well as targeted specialty and rare diseases," said Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck. "We delivered growth in the quarter while continuing to advance our mid- to long-term strategic agenda through innovation and sharpening our portfolio. Our upgraded full-year guidance reflects our confidence that Merck will continue to deliver solid performance in 2026."

Third-quarter results

Merck increased its Group net sales to € 5.6 billion (Q3 2025: € 5.3 billion). Organic growth of 5.1% was further supported by positive foreign exchange effects of 1.5%. At € 1.7 billion, EBITDA pre was around stable at +‍0.4% (Q3 2025: € 1.7 billion). As reported at the time, two one-time effects each had added a mid-double-digit million euro amount in the year-earlier quarter. The EBITDA pre margin was 29.9% (Q3 2025: 31.4%). Earnings per share pre amounted to € 2.32, reaching the same level as in the year-earlier quarter (Q3 2025: € 2.32).

Free cash flow increased by 22.7% year-on-year to € 1.3 billion in the third quarter (Q3 2025: € 1.1 billion). The strong cash generation supports Merck’s deleveraging: By the end of the quarter, net financial debt had declined by 10.3% since the beginning of the year.

All three business sectors increased net sales across regions and portfolios. Customer projects, capacity expansions and higher demand were the main drivers. With a share of 34.8% of net sales, Asia-Pacific grew by 12.1% and was once again the company’s largest market. Europe remained the second-largest market with a share of 29.1%, followed by North America at 24.5%.

Sharpened portfolio advances company strategy

In June 2026, Merck entered into a definitive agreement to acquire Bio-Techne Corporation, USA, for an enterprise value of approximately US$ 11.3 billion (€ 9.9 billion). Bio-Techne is a global provider of life science tools, analytical technologies and consumables. The acquisition significantly expands the Merck portfolio and strengthens the company’s ability to support customers from biological discovery to therapeutic development and manufacturing.

Merck also signed a definitive agreement to divest its contract development and manufacturing organization (CDMO) business within Life Science to Lonza. The transaction advances Merck’s mid- to long-term strategic agenda and is expected to close in mid-2027. It positions the CDMO business for its next phase of development under an organization with a dedicated focus on contract development and manufacturing.

In October 2026, Merck announced a definitive agreement to acquire Silence Therapeutics, United Kingdom. Once completed, the transaction will add divesiran to the Merck pipeline: The potentially best-in-class, phase III-ready siRNA investigational therapy is in development for phlebotomy-dependent polycythemia vera, a type of rare blood cancer. Divesiran is dosed subcutaneously once every three months. The planned acquisition is a strategically important step toward strengthening the company’s mid-stage pipeline and its focus on targeted specialty and rare diseases, one of Merck’s high growth value drivers. The transaction is expected to close in the first quarter of 2027.

Guidance for 2026

Based on the Group’s performance in the third quarter, Merck has raised its full year 2026 guidance. The company now expects net sales to be between € 21.5 billion and € 21.9 billion and EBITDA pre to be between € 6.2 billion and € 6.4 billion. This adjustment primarily reflects improvements in the underlying performance and more favorable foreign exchange effects. In addition, the guidance reflects the acquisition of Bio-Techne for the month of December 2026 as a portfolio effect in the Life Science business sector. This is an assumption; the actual closing date of the transaction may differ. The guidance further assumes no sales of Mavenclad in the United States from November 2026 (previous guidance: from August 2026) amid generic competition.

As a result, the implied organic growth corridor for Group net sales shifts to +‍3% to +‍4%. Organic EBITDA pre growth is now expected at +3% to +5%. Merck anticipates foreign exchange effects to impact net sales between –‍1% to 0%; for EBITDA pre, the range is –‍2% to 0%. This translates to an EPS pre between € 8.30 and € 8.70.

Life Science sustains growth momentum and sharpens portfolio focus

Life Science sustained strong underlying performance and positive momentum in the third quarter, supported by growth across its businesses and regions. Continued commercial execution under the go-to-market model and customer demand across key markets, especially Asia-Pacific, drove its performance. Net sales of Life Science reached € 2.4 billion, representing organic growth of 6.1% compared to the year-earlier quarter. Excluding the impact of tariff refunds to customers, organic growth was 7.3%. EBITDA pre was € 736 million, a strong organic increase of 8.7% year-on-year. The business sector increased R&D expenses and startup costs associated with new manufacturing sites, for example in Daejeon, Korea, to support future growth and advance its region-for-region strategy.

Process Solutions remained the main growth driver. The business unit, which offers solutions for every step of pharmaceutical manufacturing, delivered organic sales growth of 10.5% in line with the communicated normalizing growth rate in the second half of 2026. Demand was strong across downstream processing, single-use solutions, and upstream and processing materials. While underlying demand and customer capacity expansion remain strong, order book trends point to a softer fourth quarter.

Discovery Solutions, which supports research and early-stage discovery across biology, chemistry and analytical workflows, grew by 1.7% organically. Performance was supported by demand across the portfolio, with positive momentum in Asia-Pacific.

Advanced Solutions achieved organic sales growth of 4.3%. The business unit delivers tailored products and services that help customers address unique needs in high-touch and regulated environments. Both products and services contributed with growth across key regions.

In line with the innovation-led strategy of Merck, Life Science advanced a broad range of research and development initiatives. Recent launches include the continued advancement of MAST, a system that automatically collects samples during biopharmaceutical manufacturing: The first autosampler fully validated for use in commercial production under Good Manufacturing Practice standards. Its analytical integrations provide automated access to critical process and quality data, supporting faster, evidence-based process decisions. AI and digitalization also remained important areas of focus. Merck introduced new features for mConfig, including real-time trace element prediction that helps customers identify potential variability in cell culture media formulations before manufacturing. Merck also launched SYNTHIA Agentic AI, giving scientists natural-language access to retrosynthesis, reagent and safety information within compatible AI environments.

The proposed divestment of the CDMO business would further sharpen Life Science’s portfolio focus, allowing it to concentrate investments on technologies and capabilities that build on its scientific leadership. Life Science’s broad range of consumables, technologies and services will continue to support pharmaceutical, biotechnology and CDMO customers from discovery through manufacturing.

Healthcare continues to deliver strong performance in Rare Diseases

In Healthcare, Rare Diseases, Fertility & Endocrinology and Cardiometabolic contributed to growth amid tailwinds from foreign exchange effects. In the third quarter of 2026, net sales reached € 2.3 billion, an organic increase of 0.9% year-on-year. EBITDA pre remained stable at € 819 million. The organic decline of 3.6% was offset by positive foreign exchange effects of 3.8%.

Rare Diseases, a high growth value driver for Merck and a new strategic pillar in Healthcare, grew 41.5% organically. With organic growth of 80.4%, Gomekli/Ezmekly was the main growth driver. The treatment is approved for adults and children aged 2 years and older with neurofibromatosis type 1 who have plexiform neurofibromas. Sales of Ogsiveo, indicated for the treatment of progressing desmoid tumors, increased by 24.5% organically. Pimjetmi (pimicotinib), approved in China in December 2025 for the treatment of tenosynovial giant cell tumor (TGCT) also added to sales in the quarter.

Net sales in Cardiometabolic grew by 5.2% organically. This was mainly driven by double-digit growth of Concor, while Euthyrox and Glucophage also contributed positively.

Net sales in Fertility & Endocrinology increased by 3.6% organically. Pergoveris, indicated for the stimulation of follicular development in women with severe luteinizing hormone and follicle-stimulating hormone deficiency, grew organically by 14.1%. Sales of Gonal-f, a follicle-stimulating hormone treatment, were organically down by 2.4%. Saizen, for the treatment of various growth hormone disorders, recorded organic sales growth of 16.4%.

Specialty Care saw net sales decline by 10.2% organically. Erbitux, a treatment for metastatic colorectal cancer and for cancer of the head and neck, grew organically by 4.3%. This growth was supported by strong demand in Europe, in turn related to a recent label extension by the European Commission covering additional patient segments in colorectal cancer. Net sales of Mavenclad on the other hand declined by 25.1% organically, mainly reflecting generic competition in the United States.

In October, Merck announced new two-year follow-up data from the Phase III MANEUVER study, evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The data, which was presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, showed durable tumor control and sustained improvements in TGCT symptoms and joint function with pimicotinib.

On November 10, the FDA approved Pimjetmi (pimicotinib), a once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity.

Electronics: Continued strong growth supported by AI-driven demand

The Electronics business sector delivered continued strong growth in the third quarter of 2026. This development was supported by the ongoing momentum in the semiconductor industry and was driven in particular by demand from data centers and AI-related applications. Net sales increased organically by 13.3% to € 948 million. The reported increase of 8.4% included a portfolio effect of –‍5.7% from the divestment of the Surface Solutions business unit. EBITDA pre increased by 18.4% to € 279 million, driven especially by higher volumes, favorable product mix and efficient cost management.

All businesses in Semiconductor Solutions contributed to a strong organic growth of 18.7% in the third quarter, proving the strength of a broad and enabling portfolio for advanced memory and logic applications. The results reflect the sustained growth of the semiconductor industry in 2026 and were driven by demand for advanced nodes for logic and memory chips used in AI applications. These applications require increasingly complex chip architectures with higher material content per wafer and tighter process control. Consequently, demand for the high-performance specialty materials and workflow solutions offered by Merck continues to be robust.

Organic sales in Optronics declined by 0.9%. High prices for memory chips continued to weigh on end customer demand for consumer electronics, resulting in persistent price pressure and lower demand for liquid crystals. However, positive foreign exchange effects more than offset this development.

Merck continues to invest in local markets and collaborate with key players in the industry. The company recently opened a new research and development facility for materials development, scale-up and technology transfer in Sheboygan, Wisconsin, USA, as part of a US$ 200 million multi-year investment. The facility brings materials innovation closer to customers and supports the company’s focus on AI-driven wafer processing. In Eumseong, Korea, Merck opened a new production line for molybdenum-based materials. The site combines Thin Films and Delivery Systems & Services capabilities and is expected to begin commercial production following customer qualifications in 2027.

Overview of the key figures for Q3 2026

Merck Group

Key figures

€ million

Q3 2026

Q3 2025

Change

Jan.-Sept. 2026

Jan.-Sept. 2025

Change

Net sales

5,627

5,318

5.8%

16,195

15,853

2.2%

Operating result (EBIT)1

653

1,221

-46.5%

2,343

3,118

-24.8%

Margin (% of net sales)1

11.6%

23.0%

14.5%

19.7%

EBITDA2

1,615

1,679

-3.8%

4,364

4,506

-3.1%

Margin (% of net sales)1

28.7%

31.6%

26.9%

28.4%

EBITDA pre1

1,682

1,669

0.8%

4,811

4,666

3.1%

Margin (% of net sales)1

29.9%

31.4%

29.7%

29.4%

Profit after income tax

450

898

-49.9%

1,613

2,291

-29.6%

Earnings per share (€)

1.04

2.07

-49.8%

3.68

5.26

-30.0%

Earnings per share pre (€)1

2.32

2.32

–%

6.59

6.46

2.0%

Operating cash flow

1,660

1,518

9.4%

3,083

2,641

16.8%

Sept. 30, 2026

Dec. 31, 2025

Change

Net financial debt1

7,733

8,619

-10.3%

Number of employees3

61,949

62,346

-0.6%

1 Not defined by IFRS Accounting Standards (IFRS Accounting Standards).

2 Not defined by IFRS Accounting Standards; EBITDA corresponds to operating result (EBIT) adjusted by depreciation,

amortization, impairment losses, and reversals of impairment losses.

3 This figure refers to all employees at sites of fully consolidated entities.

Merck Group

Net sales by business sector

€ million

Q3 2026

Share

Organic growth1

Exchange rate effects1

Acquisitions/ divestments1

Total change

Q3 2025

Share

Life Science

2,411

43%

6.1%

1.1%

0.4%

7.6%

2,241

42%

Healthcare

2,268

40%

0.9%

2.1%

–%

2.9%

2,203

41%

Electronics

948

17%

13.3%

0.9%

-5.7%

8.4%

875

17%

Merck Group

5,627

100%

5.1%

1.5%

-0.8%

5.8%

5,318

100%

1 Not defined by IFRS Accounting Standards.

Life Science

Net sales by business unit

€ million

Q3 2026

Share

Organic growth1

Exchange rate effects1

Acquisitions/ divestments1

Total change

Q3 20252

Share

Process Solutions

1,069

44%

10.5%

1.0%

1.1%

12.6%

949

42%

Discovery Solutions

722

30%

1.7%

1.3%

–%

3.0%

701

31%

Advanced Solutions

621

26%

4.3%

1.1%

-0.3%

5.1%

591

26%

Life Science

2,411

100%

6.1%

1.1%

0.4%

7.6%

2,241

100%

1 Not defined by IFRS Accounting Standards.

2 Prior-year figures have been adjusted to reflect the transformation of the three business units.

Healthcare

Net sales by major product lines / products

€ million

Q3 2026

Share

Organic growth1

Exchange rate effects1

Acquisitions/ divestments1

Total change

Q3 2025

Share

Rare Diseases

123

5%

41.5%

2.1%

–%

43.6%

85

4%

thereof: Ogsiveo

78

3%

24.5%

1.7%

–%

26.1%

62

3%

thereof: Gomekli

43

2%

80.4%

2.7%

–%

83.1%

23

1%

Fertility & Endocrinology

514

23%

3.6%

1.2%

–%

4.8%

490

22%

thereof: Gonal-f

175

8%

-2.4%

0.4%

–%

-2.0%

179

8%

thereof: Pergoveris

91

4%

14.1%

1.5%

–%

15.6%

79

4%

thereof: Saizen

111

5%

16.4%

1.0%

–%

17.4%

94

4%

Cardiometabolic

703

31%

5.2%

4.2%

–%

9.3%

643

29%

thereof: Glucophage

267

12%

3.0%

5.5%

–%

8.5%

247

11%

thereof: Concor

179

8%

12.2%

2.2%

–%

14.4%

156

7%

thereof: Euthyrox

188

8%

6.8%

4.6%

–%

11.4%

169

8%

Specialty Care

832

37%

-10.2%

1.1%

–%

-9.1%

916

42%

thereof: Erbitux

329

14%

4.3%

1.9%

–%

6.2%

310

14%

thereof: Bavencio

128

6%

-14.1%

-0.1%

–%

-14.2%

149

7%

thereof: Mavenclad

232

10%

-25.1%

1.1%

–%

-24.0%

305

14%

thereof: Rebif

104

5%

-12.1%

0.8%

–%

-11.3%

118

5%

Other

95

4%

–%

–%

–%

–%

68

3%

Healthcare

2,268

100%

0.9%

2.1%

–%

2.9%

2,203

100%

1 Not defined by IFRS Accounting Standards.

Electronics

Net sales by business unit

€ million

Q3 2026

Share

Organic growth1

Exchange rate effects1

Acquisitions/ divestments1

Total change

Q3 20252

Share

Semiconductor Solutions

752

79%

18.7%

0.4%

–%

19.2%

631

72%

Optronics

196

21%

-0.9%

2.5%

–%

1.6%

193

22%

Surface Solutions

–

–%

–%

–%

-100.0%

-100.0%

50

6%

Electronics

948

100%

13.3%

0.9%

-5.7%

8.4%

875

100%

1 Not defined by IFRS Accounting Standards.

2 Prior-year figures have been adjusted owing to an internal realignment.

Forecast for the Merck Group

Forecast for FY 2026

€ million

Net sales

EBITDA pre1

Free cash flow

Merck Group

~21,500 to 21,900
Organic +3% to +4%
Foreign exchange effect -1% to 0%
Portfolio ~0%

~6,200 to 6,400
Organic +3% to +5%
Foreign exchange effect -2% to 0%
Portfolio ~0%

~2,300 to 2,700

Life Science

~9,400 to 9,600
Organic +6% to +7%
Foreign exchange effect -1% to 0%
Portfolio ~+1%

~2,750 to 2,850
Organic +6% to +8%
Foreign exchange effect -2% to 0%
Portfolio ~+2%

Healthcare

~8,500 to 8,700
Organic -3% to -2%
Foreign exchange effect 0% to +1%
Portfolio +2.4% (€ 207 million)

~2,900 to 3,000
Organic -5% to -3%
Foreign exchange effect 0% to +1%
Portfolio ~0%

Electronics

~3,600
Organic +10% to +11%
Foreign exchange effect -2% to -1%
Portfolio -7.0% (€ -245 million)

~1,100
Organic +33% to +35%
Foreign exchange effect 0% to +1%
Portfolio -3.3% (€ -28 million)

Corporate and Other

~-550

1 Not defined by IFRS Accounting Standards (IFRS Accounting Standards); EBITDA corresponds to operating result (EBIT) adjusted by depreciation, amortization, impairment losses, and reversals of impairment losses.

EPS pre € 8.30 to € 8.70, based on an underlying tax rate of 22%.

(Press release, Merck KGaA, NOV 12, 2026, View Source [SID1234674694])

Kazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader

On November 12, 2026 Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, reported that it will host a virtual event on Wednesday, December 2, 2026 at 4:00 PM ET featuring management’s overview of NDL2, the Company’s novel nuclear PD-L1 protein degrader designed to address mechanisms of immunotherapy resistance in advanced solid tumors, with an initial focus on metastatic breast cancer and colorectal cancer. NDL2 represents a potentially first-in-class approach within the emerging field of targeted protein degradation, a therapeutic category with no known nuclear PD-L1 protein degraders currently in clinical development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will explore the scientific discovery of NDL2 from initial concept through molecular optimization and pre-IND development, highlighting its potential to advance a differentiated approach to cancer immunotherapy. NDL2 is an optimized bicyclic peptide designed to selectively degrade disease-associated nuclear PD-L1 protein, with the goal of restoring the body’s natural anti-tumor immune response. While PD-L1 plays an important role in regulating the immune system, cancer cells can exploit this pathway to evade immune detection and resist treatment. Through targeted protein degradation (TPD), Kazia is pursuing an approach designed to harness the body’s natural protein degradation machinery to target disease-associated proteins, with the potential to overcome limitations of conventional immunotherapies.

A live question and answer session will follow the formal presentation. To register, click here. A replay of the event will be available on the Company’s website following the event.

(Press release, Kazia Therapeutics, NOV 12, 2026, View Source [SID1234674710])

Commit Biologics nominates first development candidate from BiCE™, its complement system engaging platform, and strengthens senior leadership

On November 12, 2026 Commit Biologics ("Commit"), the biotechnology company pioneering complement-powered immune engagers, reported the nomination of its first development candidate, as well as making two senior appointments, as it transitions from platform discovery to clinical development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

COM002 is the first candidate to emerge from Commit’s proprietary Bispecific Complement Engager (BiCE) platform, producing antibodies which harness the power of the complement system to safely target and eliminate specific cells. COM002 builds on Commit’s platform-validating data in non-human primates, announced in November 2025, which showed rapid, deep and sustained targeted B cell depletion with no treatment-related safety findings and without systemic cytokine release.

During 2026, Commit has built the translational data package required to support COM002’s progression to the clinic, initially targeting relapsed/refractory non-Hodgkin lymphoma, with plans to expand into several autoimmune indications.

Beyond COM002, Commit is advancing a growing pipeline of innovative therapies to unlock the broader potential of the BiCE platform across oncology and autoimmune diseases.

Mikkel Wandahl Pedersen, CSO of Commit Biologics, said: "COM002 is our first clinical development candidate of an entirely new class of immune engagers, with potential applications in cancer and autoimmune disease. The nomination is a critical milestone, as we seek to show how our BiCE platform could revolutionise treatment, just as previous classes of immunotherapies, like T cell engagers and checkpoint inhibitors, have done."

Thomas L. F. Montgomery Andresen, CEO of Commit Biologics, said: "Nominating the first complement-powered immune engager is a pivotal moment for Commit, as we look ahead to taking COM002 into the clinic and unlock the potential of our BiCE platform. It is also a great pleasure to welcome two new members of our leadership team, who both have tremendous strengths and the hands-on experience that we need."

Anne-Marie Levy Rasmussen, newly-appointed Chief Operating Officer, said: "Commit has an inspiring ambition to define a new category of medicine, and I look forward to ensuring we execute on our milestones to get BiCE antibodies to patients as fast as possible."

Benjamin Ole Wolthers, newly-appointed Head of Clinical Development, said: "Being part of Commit’s pioneering effort using the complement system in immunotherapy is a privilege. Developing COM002 will be a great opportunity to showcase the treatment possibilities of this new drug class."

Anne-Marie Levy Rasmussen brings 25 years of executive leadership in operations, commercial strategy and large-scale transformation. Most recently, she was Chief Operating Officer at Gubra. Before that, she was CEO of Innovation Fund Denmark, with a portfolio of around €1 billion, built Bavarian Nordic’s global commercial organisation, and spent 12 years in senior leadership roles at GSK. She holds an MSc in Physics from the Niels Bohr Institute, University of Copenhagen.

Benjamin Ole Wolthers is a physician scientist with strong international experience in drug development. His career started in frontline care of children with leukaemia at Rigshospitalet in Copenhagen, and he later undertook development leadership at Kite Pharma, Galapagos and most recently Evaxion. At Kite and Galapagos, he led global teams responsible for early-stage and registrational CAR-T trials, while he oversaw clinical development strategy for first-in-human trials at Evaxion. At Commit, he will lead clinical development, translational medicine and regulatory strategy, and will lead COM002 into Phase 1 trials.

(Press release, Commit Biologics, NOV 12, 2026, View Source [SID1234674727])

MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress

On November 12, 2026 MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, reported financial results for the quarter ended September 30, 2026, and highlighted recent corporate progress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"MacroGenics has made significant progress over the past year. We have strengthened our business, sharpened our pipeline development priorities, delivered on key strategic objectives and generated approximately $290 million in non-dilutive capital over the past 12 months," said Eric Risser, President and Chief Executive Officer of MacroGenics. "We are grateful to our employees and partners for their dedication and contributions to this progress. Looking ahead, we believe MacroGenics is well positioned for a year of important milestones in 2027, with multiple opportunities to demonstrate the potential of our innovative pipeline while maintaining a disciplined approach to capital allocation."

Advancement of Innovative Pipeline
MacroGenics is developing a portfolio of investigational agents, including novel topoisomerase I inhibitor-based antibody-drug conjugate (ADC), T-cell engager (TCE) and dual checkpoint inhibitor molecules.

•MGC028 is a first-in-class ADC targeting ADAM9, a protein that is overexpressed in multiple solid tumors. Phase 1 dose escalation of this molecule has been completed, and the Company has selected a lead indication. MacroGenics plans to initiate a randomized evaluation of two dose levels in this indication by year end 2026. As of a data cutoff of October 10, 2026, there were no dose-limiting toxicities, and no cases of ILD or ocular toxicity were reported. The Company intends to provide an interim clinical update, including efficacy and safety results in the lead indication, in the first half of 2027.

•MGC026 is a novel ADC targeting B7-H3, a protein expressed across the tumor microenvironment, including tumor-associated stroma and vasculature. Interim Phase 1 results were reported at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2026 Congress (link), including encouraging efficacy data and a manageable safety and tolerability profile in heavily pretreated squamous cell carcinoma of the head and neck (SCCHN) patients. The Company expects to complete enrollment of the ongoing 40-patient SCCHN Simon 2-stage monotherapy cohort by year end 2026, with updated data expected in mid-2027. In parallel, the Company will continue to evaluate the evolving competitive landscape and review the development and collaboration strategies for this molecule.

•MGC030 is a first-in-class ADC targeting an undisclosed antigen expressed across several solid tumors. Following clearance of the Investigational New Drug (IND) application, the first patient was dosed in a Phase 1 study in patients with advanced solid tumors, including urothelial, colorectal, gastric or gastroesophageal junction, esophageal and pancreatic cancers.

•Lorigerlimab is a PD-1 × CTLA-4 bispecific DART molecule being evaluated in patients with advanced gynecologic cancers. At ESMO (Free ESMO Whitepaper) 2026, the Company reported interim Phase 2 results (link) demonstrating encouraging preliminary clinical activity with single-agent lorigerlimab dosed at 6 mg/kg every three weeks (Q3W) in clear cell gynecologic cancer (CCGC). The Company expects to complete enrollment of 20 CCGC patients at a lower dose of 3 mg/kg Q3W by year end 2026, and report updated results in the first half of 2027.

Future Pipeline

MacroGenics is advancing multiple preclinical programs that incorporate proprietary platforms for next-generation TCEs and ADCs. MGD032, a novel next-generation TCE against an undisclosed target, is advancing in IND-enabling studies.

Corporate and Collaboration Updates
•Appointment of New Independent Directors. In late October, MacroGenics appointed Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., two accomplished biopharmaceutical executives with extensive oncology drug development experience, to the Company’s Board of Directors. Drs. Kuriakose and Vasconcelles have established track records guiding innovative biotechnology companies through critical stages of growth and delivering substantial shareholder value.

•Gilead Collaboration. On August 11, the Company announced that Gilead Sciences, Inc. had exercised its option to license a preclinical bispecific program under the companies’ 2022 collaboration agreement. This option exercise triggered a $10.0 million payment to MacroGenics. The Company remains eligible to earn additional milestones and royalties based on net product sales.

Third Quarter 2026 Financial Results
•Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2026, were $287.7 million, compared to $189.9 million as of December 31, 2025. During the third quarter, the Company received $119.6 million in cash consideration from Bora in connection with the sale of its GMP manufacturing operations, $24.5 million as regulatory milestone payment from Sanofi and $10.0 million option license payment from Gilead.

•Revenue: Total revenue was $18.7 million for the quarter ended September 30, 2026, compared to $53.0 million for the quarter ended September 30, 2025. The decrease was primarily due to $50.0 million in milestone revenue recognized in 2025 under the Provention (Sanofi) Asset Purchase Agreement, compared to $10.0 million recognized in 2026 related to the option exercise under the Gilead Agreement, partially offset by a $5.3 million increase in ZYNYZ royalty revenue.

•R&D Expenses: Research and development expenses were $30.6 million for the quarter ended September 30, 2026, compared to $32.7 million for the quarter ended September 30, 2025. The decrease was primarily due to lower costs related to lorigerlimab, vobramitamab duocarmazine, MGC030 manufacturing and IND-enabling activities, and certain preclinical ADCs, partially offset by increased costs related to MGC026, MGC028, MGC030 clinical activities and certain next-generation T-cell engagers.

•G&A Expenses: General and administrative expenses were $8.4 million for the quarter ended September 30, 2026, compared to $9.9 million for the quarter ended September 30, 2025. The decrease was primarily due to lower personnel-related costs, including stock-based compensation expense.
•Net Income (Loss): Net loss was $20.1 million for the quarter ended September 30, 2026, compared to net income of $16.8 million for the quarter ended September 30, 2025.
•Shares Outstanding: Shares of common stock outstanding as of September 30, 2026, were 63,875,835.
•Cash Runway Guidance: MacroGenics anticipates that its cash, cash equivalents and marketable securities of $287.7 million as of September 30, 2026, in addition to projected and anticipated future payments from partners, will support its cash runway through 2028.

(Press release, MacroGenics, NOV 12, 2026, View Source [SID1234674677])

Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer

On November 12, 2026 Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, reported plans to initiate a Phase 2 clinical trial evaluating atebimetinib in combination with chemotherapy in patients with anaplastic thyroid cancer (ATC), a highly aggressive form of thyroid cancer with significant unmet need, commonly driven by BRAF or RAS mutations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Immuneering plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the program by the end of 2026. Subject to regulatory clearance, Immuneering currently expects to dose the first patient in the study in mid-2027, with topline results potentially available 12-18 months after dosing begins. The preliminary study plan is to enroll approximately 60 patients with ATC who progressed on standard of care, including an all-comers cohort and a BRAF V600E cohort. The study is designed to be potentially registrational, pending discussion with regulators.

ATC is one of the fastest growing and most aggressive forms of cancer. While it accounts for a small percentage of all thyroid cancers, its rapid progression and poor prognosis result in a disproportionately high share of thyroid cancer-related deaths. It is commonly driven by the MAPK pathway. BRAF mutations are the most frequently occurring alterations, and the majority of patients have tumors driven by either BRAF mutations or RAS mutations. New treatment options capable of delivering durable tumor control while maintaining tolerability are urgently needed.

"Anaplastic thyroid cancer remains one of the most challenging malignancies we encounter, with tumors that can progress extraordinarily quickly and limited treatment options for many patients," said Alan Ho, M.D., Ph.D., Chief of the Head and Neck Oncology Service at Memorial Sloan Kettering Cancer Center. "Despite important advances for certain molecularly defined subsets of patients, there remains a substantial need for new therapeutic approaches that can provide durable disease control for a broader population of patients with ATC."

"Atebimetinib has the potential to help patients with many different types of cancer, and to be synergistic in many different combinations," said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering. "The exciting results we have observed to date with atebimetinib in combination with chemotherapy in pancreatic cancer has reinforced our conviction in this approach. With MAPK pathway activation a defining feature of anaplastic thyroid cancer, and BRAF and RAS mutations among its key drivers, deep cyclic inhibition of MAPK signaling with atebimetinib represents an innovative, promising therapeutic approach in combination with chemotherapy for addressing the significant unmet need in anaplastic thyroid cancer. We are grateful to the esteemed group of world-class thyroid cancer experts who have helped design this study and encouraged us to pursue it with a high degree of optimism, and together we are moving full speed ahead."

The scientific rationale supporting the planned clinical program will be highlighted in a preclinical poster at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics, taking place November 18-20, 2026, in Barcelona, Spain.

Poster Presentation Details:
Title: Atebimetinib, a deep cyclic inhibitor of MEK, combined with chemotherapy: preclinical rationale for treatment of anaplastic thyroid cancer (ATC).
Abstract Number: 144
Poster Number: PB-144
Presenter: Praveen Nair
Date: Wednesday, November 18, 2026

Following presentation, the poster is expected to be available on the publications section of Immuneering’s website.

Conference Call
Immuneering will host a conference call and live webcast at 8:30 a.m. EST on November 12, 2026, to discuss today’s news announcements. Individuals interested in listening to the live conference call may do so by dialing (800) 715-9871 for U.S. callers and (646) 307-1963 for other locations and reference conference ID 6087332, or from the webcast link in the "investors" section of the company’s website at www.immuneering.com. A webcast replay will be available in the investor relations section on the company’s website for 90 days following the completion of the call.

About Anaplastic Thyroid Cancer
Anaplastic thyroid cancer, or ATC, is a rare and highly aggressive form of thyroid cancer characterized by rapid tumor growth and invasion into surrounding tissues. According to the National Cancer Institute, ATC accounts for approximately 1% to 2% of thyroid cancer cases and affects approximately one to two people per million each year in the United States. Unlike most other forms of thyroid cancer, ATC can progress extremely rapidly and frequently presents with locally advanced or metastatic disease. Standard of care chemotherapy remains a primary treatment option for ATC, however these cytotoxic agents can induce MAPK reactivation, potentially limiting response durability. Although advances in targeted therapies have improved outcomes for some patients with specific molecular alterations, there remains a substantial unmet need for new treatment approaches capable of providing durable disease control across a broader population of patients with ATC.

About Atebimetinib
Atebimetinib is the first in a new category of oral drug candidates, Deep Cyclic Inhibitors (DCIs), designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Each of these mechanisms has been well established to improve survival in published studies. DCIs challenge the conventional model of sustained or continuous inhibition in oncology. Whereas most therapies are designed for sustained inhibition, driving cancer to adapt and develop resistance so tumors shrink quickly but temporarily, DCIs are designed to pulse faster than tumors can adapt, so tumors shrink slowly but durably. Moreover, DCIs aim to restore full transient signaling to healthy cells, with the goal of leading to fewer adverse events. Atebimetinib targets MEK, a key control point in the MAPK pathway (RAS-RAF-MEK-ERK), which is pathologically activated in a majority of cancers, including approximately 97% of pancreatic cancers. Targeting MEK blocks a broader range of MAPK pathway alterations because it is further downstream, creating the potential for more durable benefit.

(Press release, Immuneering, NOV 12, 2026, View Source [SID1234674695])